Basic | |
---|---|
Market Cap | $1.8M |
Price | $9.44 |
52 Week Range | 1.31-12.027 |
Beta | 0.45 |
Margins | |
Gross Profit Margin | 38.02% |
Operating Profit Margin | -5378.48% |
Net Profit Margin | -7559.37% |
Valuation (TTM) | |
P/E Ratio | -0.76 |
Price to Sales Ratio | 60.48 |
Price to Book Ratio | -22.77 |
PEG Ratio | -0.02 |
Biotechnology
Healthcare
4
2017-06-27T00:00:00.000Z
1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
650 507 0669
Building 4, Palo Alto, CA, 94306, US
0001690080